
THC's hospital growth is fueling earnings momentum as stronger volumes, revenues and margins help offset exchange weakness.
Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.
| Revenue (TTM) | $21.81B |
| Gross Profit (TTM) | $9.09B |
| EBITDA | $4.84B |
| Operating Margin | 18.20% |
| Return on Equity | 37.30% |
| Return on Assets | 8.32% |
| Revenue/Share (TTM) | $252.49 |
| Book Value | $57.86 |
| Price-to-Book | 4.63 |
| Price-to-Sales (TTM) | 0.98 |
| EV/Revenue | 1.442 |
| EV/EBITDA | 5.85 |
| Quarterly Earnings Growth (YoY) | 213.40% |
| Quarterly Revenue Growth (YoY) | 6.80% |
| Shares Outstanding | $80.52M |
| Float | $79.54M |
| % Insiders | 1.13% |
| % Institutions | 102.63% |
Volatility is currently contracting

THC's hospital growth is fueling earnings momentum as stronger volumes, revenues and margins help offset exchange weakness.

Top-ranked stocks CNC, THC, FTNT, U and GS are likely to beat on the bottom line in their upcoming releases.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tenet (THC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ROKU, THC and CZFS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 12, 2026.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

CNR, IX, THC, SOLS and KMX have been added to the Zacks Rank #1 (Strong Buy) List on August 12, 2026.

Tenet Healthcare Corporation (THC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, THC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

The ETF landscape has plenty of ways to signal momentum or positive news for ETFs, from tech charts to raw performance data. One key data point, however, is the three year anniversary of a fund's launch.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on THC and any ticker you trade — then tracks every position and per-strategy win rate.